<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Ciencias Cardiovasculares > Trombosis y hemostasia > DA - CIMA - Cardiovasculares - Trombosis y Hemostasia - Artículos de Revista >

Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol
Authors: Hermida, J. (José)
Zarza, J. (José)
Alberca, I. (Ignacio)
Montes, R. (Ramón)
Lopez, M.L. (María Luz)
Molina, E. (Eva)
Rocha, E. (Eduardo)
Keywords: Acenocoumarol/pharmacology
Aryl Hydrocarbon Hydroxylases
Cytochrome P-450 Enzyme System/genetics
Genetic Variation
Polymorphism, Genetic
Steroid 16-alpha-Hydroxylase
Steroid Hydroxylases/genetics
Issue Date: 2002
Publisher: American Society of Hematology
Publisher version:
ISSN: 1528-0020
Citation: Hermida J, Zarza J, Alberca I, Montes R, Lopez ML, Molina E, et al. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood 2002 Jun 1;99(11):4237-4239.
The 2C9*3 and 2C9*2 polymorphisms of cytochrome P-450 CYP2C9 are associated with hypersensitivity to warfarin and bleeding. The effect of these polymorphisms on sensitivity to acenocoumarol is unknown. Three groups of patients, with low, medium, or high acenocoumarol-dose requirements, were studied. Age influenced the acenocoumarol sensitivity. Bearing the 2C9*3 allele was associated with the need for a lower acenocoumarol dose (odds ratio [OR], 6.02; 95% confidence interval [CI], 1.50-24.18); 80% of carriers of the 2C9*3 allele required a low dose. The 2C9*2 allele was associated with a lower acenocoumarol-dose requirement (OR, 2.70; 95% CI, 1.11-6.58) because of a reduced risk of the need for a high acenocoumarol dose (4.8% of the patients in the high-dose group carried the 2C9*2 allele versus 34.1% and 30.2%, respectively, in the medium-dose and low-dose groups). Therefore, carriers of 2C9*3 may need a low initial loading dose of acenocoumarol. Because acenocoumarol sensitivity with the 2C9*2 variant does not seem to be clinically relevant, the drug could be an alternative to warfarin in 2C9*2 carriers
Permanent link:
Appears in Collections:DA - CIMA - Cardiovasculares - Trombosis y Hemostasia - Artículos de Revista

Files in This Item:
File:  Blood2002_994237.pdf
Size:  141,68 kB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.